Targepeutics is a biopharmaceutical company developing selective molecularly targeted therapeutics to fight cancer and other diseases. Our lead compound, GB-13, is currently nearing Phase I clinical trials for high-grade giloma (brain cancer), and is showing promise against other solid tumors. GB-13 is a genetically engineered recombinant protein that specifically binds and destroys cancer cells with minimal normal cell damage.

For additional information, please contact:

Targepeutics, Inc.

475 West Governor Road
Hershey, PA 17033

Sil Lutkewitte, President
Phone: (717) 571-2402
Email: slutkewitte@targepeutics.com

Stephan B. Abramson, VP, Clinical and Regulatory Affairs
Phone: (360) 574-3363
Email: abramson@lifescipartners.net

Lynn Maines, Ph.D., M.B.A., VP, Business Development
Phone: (717) 215-9409
Email: lmaines@usa.net